100
Participants
Start Date
May 15, 2023
Primary Completion Date
August 14, 2025
Study Completion Date
August 14, 2025
TTI-101
Orally via a tablet.
Placebo
Orally via a tablet.
New York University Langone Pulmonary and Critical Care Associates, Brooklyn
Icahn School of Medicine at Mount Sinai, New York
Penn State Health Milton S. Hershey Medical Center, Hershey
Saint Luke's University Hospital - Bethlehem, Bethlehem
Temple University Hospital, Philadelphia
Inova Fairfax Medical Campus, Falls Church
Pulmonix, Greensboro
The Medical University of South Carolina, Charleston
Emory University Hospital, Atlanta
University of Florida, Gainesville
UHealth - University of Miami Health Systems, Miami
Saint Francis Sleep Allergy and Lung Institute, Clearwater
The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham
Clinical Trials Center of Middle Tennessee, Franklin
University of Iowa Hospitals and Clinics, Iowa City
Loyola University Medical Center, Maywood
Northwestern University, Chicago
University of Chicago Medicine, Chicago
The Lung Research Center, Chesterfield
Metroplex Pulmonary and Sleep Center, McKinney
Baylor Scott & White Center for Advanced Heart & Lung Disease, Dallas
Baylor College of Medicine, Houston
University of Texas Health Science Center at Houston (UT Health), Houston
University of Colorado School of Medicine, Aurora
University of California San Diego, La Jolla
University of California Irvine (UCI) Health, Orange
Tulane University School of Medicine, New Orleans
Salem Chest Specialists, Winston-Salem
Tvardi Therapeutics, Incorporated
INDUSTRY